2010 Apr;151(4):1473-86 Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjgren I, Andersen S, Andersen L, de Boer AS, Manova K, Barlas A, Vundavalli S, Nyborg NC, Knudsen LB, Moelck AM, Fagin JA
To view a copy of this licence, visit About this article Cite this article Movahednasab, M., Dianat-Moghadam, H., Khodadad, S
In longevity circles, experts such as Dr
Mller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1)
We explore the consultation background, the regulatory concerns driving it and what it could mean for clubs with existing or future sponsorship deals
that reductive labeling of GLP-1 medications as subterfuge of the hard work and willpower required to shed excess weight is not accurate, nor is it helpful to any rational discussion of the potentially wide-ranging health benefits this group of medications appears to provide